BROWN RUDNICK LLP for HOSPIRA, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 18, 2013 | $50,000 | Replaced |
| 4th Quarter - Amendment | Jan 18, 2013 | $50,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act; Senate Draft Proposal to Improve Drug Distribution Security.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LAYMAN | SPA, Sen Stabenow(05-07) |
| HENRY W MENN | Min SD & Counsel, Cmte on Vet Affairs (04) |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.